Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01213082 · ClinicalTrials.gov registry record · Phase 1
ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01213082 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 34 participants.
The verdict
NCT01213082, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that proton beam irradiation combined with intravitreal anti-VEGF therapy is safe and potentially more effective than intravitreal anti-VEGF therapy alone in eyes with exudative age-related macular degeneration.
Interventions
- DRUG 24GyE proton and Anti-VEGF
- DRUG 16GyE and anti-VEGF
- DRUG Sham Irradiation and anti-VEGF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-09 |
| Est. Completion | 2017-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01213082
The ClinicalTrials.gov registry entry for NCT01213082 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 24GyE proton and Anti-VEGF is the first listed.
NCT01213082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01213082 about?
NCT01213082 is a clinical study titled "ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)". The purpose of this study is to test the hypothesis that proton beam irradiation combined with intravitreal anti-VEGF therapy is safe and potentially more effective than intravitreal anti-VEGF therapy alone in eyes with exudative age-related macular degeneration.
What is the current status of trial NCT01213082?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2010-09. Estimated completion is 2017-01-31.
What interventions are being tested in trial NCT01213082?
The interventions under investigation include: 24GyE proton and Anti-VEGF (DRUG), 16GyE and anti-VEGF (DRUG), Sham Irradiation and anti-VEGF (DRUG).
Who is sponsoring clinical trial NCT01213082?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.